Latest myelodysplastic syndromes Stories
Insightful research report “Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics” worked out by MP Advisors
Scientists have uncovered a critical genetic mutation in some patients with myelodysplastic syndromes — a group of blood cancers that can progress to a fatal form of leukemia.
The John Theurer Cancer Center at Hackensack University Medical Center announced today that it will present research updates and clinical trial results of 40 cutting-edge studies at the 52nd Annual American Society of Hematology (ASH) Meeting in Orlando from December 4 â€“ 6.
WALTHAM, Mass., April 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Celgene's Vidaza (azacitidine) (seven-day dosing) will retain Decision Resources' proprietary clinical gold standard status through 2013 for the treatment of high-risk myelodysplastic syndromes.
WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ -- Eisai Inc. today announced that the U.S.
WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S.
The Need for More-Efficacious Treatments Creates Significant Opportunity for Drug Developers in this Niche Market, According to a New Report from Decision Resources WALTHAM, Mass., May 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2012, growth in the myelodysplastic syndromes drug market will be driven principally by the launch in Europe of Celgene's Vidaza and Revlimid.
- Withering but not falling off, as a blossom that persists on a twig after flowering.